Correlation Between Fennec Pharmaceuticals and Capricor Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Fennec Pharmaceuticals and Capricor Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fennec Pharmaceuticals and Capricor Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fennec Pharmaceuticals and Capricor Therapeutics, you can compare the effects of market volatilities on Fennec Pharmaceuticals and Capricor Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fennec Pharmaceuticals with a short position of Capricor Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fennec Pharmaceuticals and Capricor Therapeutics.

Diversification Opportunities for Fennec Pharmaceuticals and Capricor Therapeutics

-0.75
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Fennec and Capricor is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Fennec Pharmaceuticals and Capricor Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Capricor Therapeutics and Fennec Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fennec Pharmaceuticals are associated (or correlated) with Capricor Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Capricor Therapeutics has no effect on the direction of Fennec Pharmaceuticals i.e., Fennec Pharmaceuticals and Capricor Therapeutics go up and down completely randomly.

Pair Corralation between Fennec Pharmaceuticals and Capricor Therapeutics

Given the investment horizon of 90 days Fennec Pharmaceuticals is expected to under-perform the Capricor Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Fennec Pharmaceuticals is 1.78 times less risky than Capricor Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Capricor Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  422.00  in Capricor Therapeutics on October 22, 2024 and sell it today you would earn a total of  948.00  from holding Capricor Therapeutics or generate 224.64% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Fennec Pharmaceuticals  vs.  Capricor Therapeutics

 Performance 
       Timeline  
Fennec Pharmaceuticals 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Fennec Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Fennec Pharmaceuticals exhibited solid returns over the last few months and may actually be approaching a breakup point.
Capricor Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Capricor Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Fennec Pharmaceuticals and Capricor Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Fennec Pharmaceuticals and Capricor Therapeutics

The main advantage of trading using opposite Fennec Pharmaceuticals and Capricor Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fennec Pharmaceuticals position performs unexpectedly, Capricor Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will offset losses from the drop in Capricor Therapeutics' long position.
The idea behind Fennec Pharmaceuticals and Capricor Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets